Last reviewed · How we verify
Incomplete miscarriage — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Oxytocin 5 Usp Units In Dextrose 5% | OXYTOCIN | Fresenius Kabi | Adrenocorticotropic Hormone [EPC] | Oxytocin receptor | 1980-01-01 | |
| Prepidil | DINOPROSTONE | Pfizer | Prostaglandin Analog [EPC] | Prostaglandin E2 receptor EP4 subtype | 1977-01-01 | |
| Enzaprost | DINOPROST | Pfizer | dinoprost | Prostaglandin F2-alpha receptor | 1976-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 2 drugs in Incomplete miscarriage
- Fresenius Kabi · 1 drug in Incomplete miscarriage
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Incomplete miscarriage:
- Incomplete miscarriage treatment updates — RSS
- Incomplete miscarriage treatment updates — Atom
- Incomplete miscarriage treatment updates — JSON
Cite this brief
Drug Landscape (2026). Incomplete miscarriage — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/incomplete-miscarriage. Accessed 2026-06-10.
Related
- Incomplete miscarriage full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing